FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386854093> ?p ?o ?g. }

• W4386854093 endingPage "6" @default.
• W4386854093 startingPage "1" @default.
• W4386854093 abstract "Background. Given the chronic relapsing, remitting course of psoriasis, data about long-term effectiveness may be useful to assess the maintenance of clinical response over time. Objective. To evaluate 2-year drug survival of risankizumab and identify any predictive factor of discontinuation for ineffectiveness. Materials and Methods. A multicenter retrospective study was conducted in patients who initiated risankizumab between July 2019 and December 2020. PASI was measured at baseline and after 104 weeks. Any adverse event was registered during visits. Univariable and multivariable logistic regressions were used to assess baseline patients’ characteristics that predicted clinical response. The drug survival analysis was descriptively performed using the Kaplan–Meier survival curve. Results. 112 patients with moderate-to-severe plaque psoriasis were included. The overall median observation time was 35.3 months (26.7–37.3); the estimated survivor cumulative function at months 12 and 24 was 93.6% and 90.6%, respectively. No differences in BMI, disease duration, disease severity, or previous biological therapies were observed in patients who responded or did not respond to treatment. No significant adverse events were reported, but there was relapse of psoriatic arthritis and ulcerative colitis in a patient. Conclusions. We found that risankizumab was associated with long-term effectiveness, and a favorable safety profile in a population of psoriatic patients was observed, over a period of 2 years." @default.
• W4386854093 created "2023-09-20" @default.
• W4386854093 creator A5000163818 @default.
• W4386854093 creator A5004401304 @default.
• W4386854093 creator A5005493579 @default.
• W4386854093 creator A5006731288 @default.
• W4386854093 creator A5014765702 @default.
• W4386854093 creator A5017909108 @default.
• W4386854093 creator A5018495576 @default.
• W4386854093 creator A5027650355 @default.
• W4386854093 creator A5030077978 @default.
• W4386854093 creator A5036093206 @default.
• W4386854093 creator A5045083630 @default.
• W4386854093 creator A5061743711 @default.
• W4386854093 creator A5065547176 @default.
• W4386854093 creator A5073067783 @default.
• W4386854093 creator A5073673830 @default.
• W4386854093 creator A5075659127 @default.
• W4386854093 creator A5083046616 @default.
• W4386854093 creator A5083362670 @default.
• W4386854093 creator A5084739387 @default.
• W4386854093 creator A5088755599 @default.
• W4386854093 date "2023-09-19" @default.
• W4386854093 modified "2023-10-02" @default.
• W4386854093 title "2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy" @default.
• W4386854093 cites W2989256809 @default.
• W4386854093 cites W3127388240 @default.
• W4386854093 cites W3143775625 @default.
• W4386854093 cites W3164696742 @default.
• W4386854093 cites W3173878348 @default.
• W4386854093 cites W3199340815 @default.
• W4386854093 cites W3204010602 @default.
• W4386854093 cites W3207194448 @default.
• W4386854093 cites W4205527272 @default.
• W4386854093 cites W4213032959 @default.
• W4386854093 cites W4223634396 @default.
• W4386854093 cites W4281795623 @default.
• W4386854093 cites W4294622315 @default.
• W4386854093 cites W4306315330 @default.
• W4386854093 cites W4309213932 @default.
• W4386854093 cites W4321378026 @default.
• W4386854093 cites W4364369917 @default.
• W4386854093 cites W4367598330 @default.
• W4386854093 doi "https://doi.org/10.1155/2023/9832296" @default.
• W4386854093 hasPublicationYear "2023" @default.
• W4386854093 type Work @default.
• W4386854093 citedByCount "0" @default.
• W4386854093 crossrefType "journal-article" @default.
• W4386854093 hasAuthorship W4386854093A5000163818 @default.
• W4386854093 hasAuthorship W4386854093A5004401304 @default.
• W4386854093 hasAuthorship W4386854093A5005493579 @default.
• W4386854093 hasAuthorship W4386854093A5006731288 @default.
• W4386854093 hasAuthorship W4386854093A5014765702 @default.
• W4386854093 hasAuthorship W4386854093A5017909108 @default.
• W4386854093 hasAuthorship W4386854093A5018495576 @default.
• W4386854093 hasAuthorship W4386854093A5027650355 @default.
• W4386854093 hasAuthorship W4386854093A5030077978 @default.
• W4386854093 hasAuthorship W4386854093A5036093206 @default.
• W4386854093 hasAuthorship W4386854093A5045083630 @default.
• W4386854093 hasAuthorship W4386854093A5061743711 @default.
• W4386854093 hasAuthorship W4386854093A5065547176 @default.
• W4386854093 hasAuthorship W4386854093A5073067783 @default.
• W4386854093 hasAuthorship W4386854093A5073673830 @default.
• W4386854093 hasAuthorship W4386854093A5075659127 @default.
• W4386854093 hasAuthorship W4386854093A5083046616 @default.
• W4386854093 hasAuthorship W4386854093A5083362670 @default.
• W4386854093 hasAuthorship W4386854093A5084739387 @default.
• W4386854093 hasAuthorship W4386854093A5088755599 @default.
• W4386854093 hasBestOaLocation W43868540931 @default.
• W4386854093 hasConcept C10515644 @default.
• W4386854093 hasConcept C126322002 @default.
• W4386854093 hasConcept C141071460 @default.
• W4386854093 hasConcept C16005928 @default.
• W4386854093 hasConcept C167135981 @default.
• W4386854093 hasConcept C197934379 @default.
• W4386854093 hasConcept C2776260265 @default.
• W4386854093 hasConcept C2777011040 @default.
• W4386854093 hasConcept C2778715236 @default.
• W4386854093 hasConcept C2779134260 @default.
• W4386854093 hasConcept C2780564577 @default.
• W4386854093 hasConcept C2908647359 @default.
• W4386854093 hasConcept C50382708 @default.
• W4386854093 hasConcept C71924100 @default.
• W4386854093 hasConcept C99454951 @default.
• W4386854093 hasConceptScore W4386854093C10515644 @default.
• W4386854093 hasConceptScore W4386854093C126322002 @default.
• W4386854093 hasConceptScore W4386854093C141071460 @default.
• W4386854093 hasConceptScore W4386854093C16005928 @default.
• W4386854093 hasConceptScore W4386854093C167135981 @default.
• W4386854093 hasConceptScore W4386854093C197934379 @default.
• W4386854093 hasConceptScore W4386854093C2776260265 @default.
• W4386854093 hasConceptScore W4386854093C2777011040 @default.
• W4386854093 hasConceptScore W4386854093C2778715236 @default.
• W4386854093 hasConceptScore W4386854093C2779134260 @default.
• W4386854093 hasConceptScore W4386854093C2780564577 @default.
• W4386854093 hasConceptScore W4386854093C2908647359 @default.
• W4386854093 hasConceptScore W4386854093C50382708 @default.
• W4386854093 hasConceptScore W4386854093C71924100 @default.

• next